

Amoéba launches a massive new field trials campaign for 2021

Chassieu (France), April 6, 2021 – 8.30 am- AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in a development phase, announces within the development of its biofungicide active substance, the lysate of the amoeba *Williaertia magna* C2c Maky, that it extends its collaborations with its partners (**PHILAGRO and STÄHLER**) and other major actors of the plant protection sector (**BASF - BAYER - EVERGREEN GARDEN CARE - GOWAN - KWIZDA**).

Continued experimentation with partners

PHILAGRO (France) and **STÄHLER** (Switzerland), the partner companies with which AMOÉBA has already signed term sheets that will lead to the signature of distribution agreements on grapevines¹, will continue their experiments on grapevines but also on other crops.

Biocontrol application tested on other crops and geographical areas

Other agrochemical players, some of whom have already conducted tests in 2020, have decided to take part in this new field trials campaign. **BASF - BAYER - EVERGREEN GARDEN CARE - GOWAN - KWIZDA** will test the active substance of AMOÉBA in different countries and on a wide range of crops (including vines, cereals and vegetables).

With the trials carried out by AMOÉBA itself, a total of more than **200 trials** are planned throughout the world (Europe, the Americas, Asia) in 2021. This very large campaign will enable us to deepen our knowledge of the active substance, compare several formulations, broaden our knowledge of the spectrum of activity and generate, in Europe, results that will be used in future marketing authorization applications for formulated biocontrol products.

"This new field trials campaign, in which new agrochemical players will take part, demonstrates the need to act quickly to find alternatives to chemicals. Today's agriculture, faced with more and more restrictions on the use of plant protection products, has to take up many environmental challenges to meet the expectations of the market and consumers. With 200 trials scheduled, including more than 70 of its own, AMOÉBA and its partners are determined to support all the players in the agricultural world in order to bring about a genuine agro-ecological transition", says Fabrice PLASSON, President and CEO of Amoéba.

¹ See press releases of December 9 and 18, 2020

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.